Cerebrospinal fluid biomarkers of B-amyloid metabolism in MS

This study looked at amyloid precursor protein (APP) degradation products in the CSF of MS patients at different stages of disease, in addition to the effects of disease modifying therapy. CSF samples were obtained from 87 MS patients, including 54 RRMS, 33 SPMS and 28 controls. They found that CSF APP and Aβ (Amyloid Beta) peptide levels were reduced in MS patients, however they increased towards normal after natalizumab therapy. This may be due to natalizumab counteracting the altered APP metabolism in MS. The combined pattern of Aβ peptide allowed them to distinguish between controls and SPMS patients.

This study highlights the complexities of APP metabolism in neuroinflammation. Further studies are needed to increase our understanding of the role of APP metabolism in MS.

Augutis K, Axelsson M, Portelius E

Mult Scler. 2012 Oct 15. [Epub ahead of print]

Read the abstract


Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial